Zobrazeno 1 - 10
of 41
pro vyhledávání: '"R. D. Harvey"'
Autor:
Terence Hall, Yunxia Wang, Bassel F. El-Rayes, Patricia LoRusso, Walid L. Shaib, Jasgit C. Sachdev, Ronald E. Savage, R. D. Harvey, Giovanni Abbadessa, Julia Kazakin, Drew W. Rasco, Amita Patnaik, Brian Schwartz, Kyriakos P. Papadopoulos, Anthony W. Tolcher
Publikováno v:
British Journal of Cancer
Background: ARQ 087 is an orally administered pan-FGFR inhibitor with multi-kinase activity. This Phase 1 study evaluated safety, pharmacokinetics, and pharmacodynamics of ARQ 087 and defined the recommended Phase 2 dose (RP2D). Methods: Patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7ff18df66d5caa1b78e0dc94c879869
http://europepmc.org/articles/PMC5729432
http://europepmc.org/articles/PMC5729432
Autor:
Roberto Mina, R. D. Harvey, T. L. Zimmerman, Jonathan L. Kaufman, Thomas Martin, J. J. Wolf, Ajay K. Nooka, Charise Gleason, Cathy Sharp, Leonard T. Heffner, Colleen Lewis, Andrzej Jakubowiak, Sagar Lonial
Publikováno v:
Blood Cancer Journal
Blood Cancer Journal, Vol 9, Iss 1, Pp 1-9 (2019)
Blood Cancer Journal, Vol 9, Iss 1, Pp 1-9 (2019)
Proteasome (PIs) and hystone deacetylase inhibitors (HDACis) have previously shown synergistic activity in the treatment of relapesed/refractory multiple myeloma (RRMM) patients. In this phase 1 study, we combined carfilzomib, a second generation PI,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69f9ef099caaabb2a3443866fafb75e9
http://hdl.handle.net/2318/1732448
http://hdl.handle.net/2318/1732448
Autor:
C. O. Landgren, K. Lucero, B. Faiman, L. Willis, R. D. Harvey, C. Cason, M. Tanzola, Alexander Keith Stewart, S. Lonial, Ravi Vij
Publikováno v:
HemaSphere. 3:968-969
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31908e30ba09848b521a56cccb7150d2
https://doi.org/10.1097/01.hs9.0000567104.86214.98
https://doi.org/10.1097/01.hs9.0000567104.86214.98
Autor:
R. D. Harvey
Publikováno v:
Clinical Pharmacology and Therapeutics
Therapeutic antibodies that block the programmed cell death protein-1 (PD-1) immune checkpoint pathway prevent T-cell downregulation and promote immune responses against cancer. Several PD-1 pathway inhibitors have shown robust activity in initial tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9761e7359a128a17e31727e728987784
http://europepmc.org/articles/PMC5685326
http://europepmc.org/articles/PMC5685326
Autor:
Dong M. Shin, Bassel F. El-Rayes, Fadlo R. Khuri, Mourad Tighiouart, Colleen Lewis, Michael Fanucchi, Andre Rogatko, R. D. Harvey, P Nadella, Suresh S. Ramalingam, A. Akintayo, John S. Kauh, Zhengjia Chen, Taofeek K. Owonikoko
Publikováno v:
British Journal of Cancer
Background: This phase 1 trial utilising a Bayesian continual reassessment method evaluated bortezomib and sunitinib to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended doses of the combination. Methods: Pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a374dd71a823c0fd0fd0fe730834f84c
https://doi.org/10.1038/bjc.2012.604
https://doi.org/10.1038/bjc.2012.604
Autor:
Benjamin Wu, Michael L. Maitland, Afshin Dowlati, Lionel D. Lewis, Erick Gamelin, Erik Rasmussen, Yu-Nien Sun, Jay L. Koyner, R. D. Harvey, Gregory Friberg
Publikováno v:
Clinical pharmacology and therapeutics. 102(2)
Clearance of trebananib (AMG 386), a 64-kD antiangiogenic peptibody, has been associated with estimated glomerular filtration rate (eGFR). We prospectively evaluated trebananib pharmacokinetics and safety/tolerability in advanced solid tumor patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::121ec4f021cb08b8c7ef743d49681a12
https://pubmed.ncbi.nlm.nih.gov/28074547
https://pubmed.ncbi.nlm.nih.gov/28074547
Autor:
P F Sharp, Keith A Goatman, G. Sell, R. D. Harvey, J. A. Olson, K Swa, Sam Philip, Caroline Styles, N. Lee, Alan Fleming, Mairead Black
Publikováno v:
Diabetic Medicine. 29:776-783
Diabet. Med. 29, 776–783 (2012) Abstract Aims To develop and evaluate an image grading external quality assurance system for the Scottish Diabetic Retinopathy Screening Programme. Method A web-based image grading system was developed which closely
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8207ff12d46e917e95887e540689a0a2
https://doi.org/10.1111/j.1464-5491.2011.03504.x
https://doi.org/10.1111/j.1464-5491.2011.03504.x
Publikováno v:
Haemophilia. 20:e344-e346
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::669eb044e1d7f0de3decc2a6bea4e749
https://doi.org/10.1111/hae.12452
https://doi.org/10.1111/hae.12452
Autor:
R. D. Harvey, W. Wu, M. Muhsin, E.L. Pham, Adrian Murphy, Mohamedtaki Abdulaziz Tejani, Edward J. Kim
Publikováno v:
Annals of Oncology. 29:ix54
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0d816e60b1957f7ce94006f637b8d3d
https://doi.org/10.1093/annonc/mdy432.022
https://doi.org/10.1093/annonc/mdy432.022
Autor:
Bassel El-Rayes, Christopher A. Staley, D. Cardin, Dong M. Shin, L. Goff, Nabil F. Saba, Jonathan J. Beitler, J.C. Nesbitt, S.S. Ramalingam, R. D. Harvey, Felix G. Fernandez, W. El-Rifai, F.F. Willingham, Eric S. Lambright, Seth D. Force, A. Pickens, Zhengjia Chen, Anuradha Bapsi Chakravarthy, Kenneth Cardona, Taofeek K. Owonikoko, Kristin Higgins, S. Salaria, J.C. Landry
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 102:e27
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cbbe8c8d1fd34c23ccdb971d6a5ba5b8
https://doi.org/10.1016/j.ijrobp.2018.07.510
https://doi.org/10.1016/j.ijrobp.2018.07.510